TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from BCAL Diagnostics Limited ( (AU:BDX) ).
BCAL Diagnostics Limited has received approximately $2.5 million from the Australian Government’s R&D Tax Incentive, aiding its development of early cancer detection tests. This funding supports the commercial launch and enhancement of its BREASTEST plus™ product, which now covers 50% of eligible women with dense breasts, bolstering BCAL’s position in the women’s health sector.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is an Australian healthcare company focused on early cancer detection. It has launched BREASTEST plus™, a non-invasive blood test designed to improve breast disease screening and diagnostics for women with dense breasts. BCAL holds exclusive licenses for precision diagnostic tests from ClearNote Health Inc. and is listed on the Australian Securities Exchange.
Average Trading Volume: 474,638
Technical Sentiment Signal: Buy
Current Market Cap: A$33.84M
For an in-depth examination of BDX stock, go to TipRanks’ Overview page.